Ranbaxy, Daiichi to intergrate R&D unit; Report: Price cuts hamper drug development;

@FierceBiotech: Abraxis' billionaire chief is adding to his blockbuster bank account. Article | Follow @FierceBiotech

@JohnCFierce: Now that the great swine flu pandemic has ended with a giant public shrug, health officials will burn 40M doses of vax. Article | Follow @JohnCFierce

> Ranbaxy and Daiichi Sankyo to integrate new drug R&D unit. Report

> Angered by the moves European nations are taking to cut drug prices, one big drugmaker commissioned a study that finds--guess what?--price cuts will severely reduce the number of new meds making it to market. Story

> Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today a series of management changes, including revised job responsibilities, designed to position the organization for long-term success. Release

> Shares of Ironwood Pharmaceuticals Inc. fell after a Credit Suisse analyst initiated coverage of the stock with a "Neutral" rating, saying sales potential for its drug linaclotide is already priced into the stock. Story

> There is a relief for people suffering from baldness, as a recent genetic discovery claims to have found genes associated with baldness and this ultimately means that there is a scope for cure of this disease of hair loss. Item

And Finally... Long banished behind steel barriers, robots are entering new fields of application such as the household and healthcare sectors. The requisite safety can be provided by a tactile sensor system, which can be integrated in a floor or applied to robots as an artificial skin. Report

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.